Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

HealthDay News — In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are ...

During the 43rd J.P. Morgan Annual Healthcare Conference last month, Areteia Therapeutics took centre stage, presenting a ...

A multi-institutional study has identified one of the allergens responsible for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus. This is the first time one of the allergens ...

A multi-institutional study led by researchers at Children's Hospital of Philadelphia (CHOP) is the first to identify one of ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., ...

Researchers at the, Riverside, backed by a substantial NIH grant, are pioneering a study on the unique immune responses to ...

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Medically reviewed by Jay N. Yepuri, MD Eosinophilic esophagitis (EoE) occurs when white blood cells called eosinophils build ...

Conversely, if a loved one appears distant or fed up—for example, is thinking about ending the relationship—the person with ...